Do Spiriva (tiotropium) and Breztri Aerosphere (glycopyrrolate/formoterol/budesonide) work the same, and is it appropriate to switch a COPD patient from Spiriva to Breztri?

Breztri Aerosphere and Spiriva Do Not Work the Same—Switching is Appropriate and Evidence-Based

Breztri Aerosphere (budesonide/glycopyrrolate/formoterol) is a triple therapy medication that contains three active ingredients, while Spiriva (tiotropium) is a single long-acting muscarinic antagonist (LAMA) bronchodilator—the pulmonologist's recommendation to switch represents an escalation to more comprehensive therapy that is strongly supported by current guidelines for patients with moderate-to-severe COPD. 1

Key Differences Between the Medications

Spiriva (Tiotropium) Monotherapy

• Contains only one medication class: a long-acting muscarinic antagonist (LAMA) that provides 24-hour bronchodilation 1, 2
• Recommended as first-line maintenance therapy for moderate-to-severe COPD with Grade 1A evidence 2
• Reduces exacerbations compared to placebo with an odds ratio of 0.71 (95% CI, 0.52-0.95) 1

Breztri Aerosphere Triple Therapy Components

• Glycopyrrolate: A LAMA (same class as Spiriva's tiotropium) providing 24-hour bronchodilation 3
• Formoterol: A long-acting beta-agonist (LABA) that works through a different mechanism than LAMAs, providing additional bronchodilation 4
• Budesonide: An inhaled corticosteroid (ICS) that reduces airway inflammation 5, 6

Why Triple Therapy is Superior for Appropriate Patients

Mortality Benefit

• Triple therapy (LAMA/LABA/ICS) reduces all-cause mortality compared to dual LAMA/LABA therapy in high-risk patients, with a hazard ratio of 0.54-0.64 depending on the specific formulation 1
• This mortality benefit is maintained even after excluding the first 30 days of treatment and has been confirmed by independent adjudication 1

Exacerbation Reduction

• Triple therapy provides superior exacerbation prevention compared to LAMA monotherapy 1, 5
• In patients switching from dual therapy to budesonide/glycopyrrolate/formoterol (Breztri), exacerbation rates decreased by 11.6% 7
• When switching from other triple therapies to Breztri, exacerbation rates decreased by 15.5% 7

Symptom Control and Quality of Life

• Triple therapy significantly improves dyspnea, exercise tolerance, and health status compared to LAMA monotherapy 1, 5
• Rescue medication use (particularly short-acting beta-agonists) declined by 23.2% after escalation from dual therapy to Breztri 7

Who Should Receive Triple Therapy Instead of LAMA Monotherapy

Strong Indications for Triple Therapy (Breztri)

• Patients with high exacerbation risk: ≥2 moderate exacerbations OR ≥1 severe exacerbation (requiring hospitalization) in the past year 1
• Patients with high symptom burden: CAT score ≥10 or mMRC dyspnea scale ≥2 1
• Patients with FEV1 <80% predicted 1
• Patients with persistent symptoms despite LAMA or LAMA/LABA therapy 7, 8

Real-World Evidence Supporting the Switch

• In the AURA study, 57.9% of patients initiating Breztri had evidence of COPD exacerbations despite current therapy 8
• 54.3% had required oral corticosteroid fills in the prior year, indicating inadequate control 8
• After switching to Breztri, emergency room visits decreased by 19.7-29.4% and hospitalizations decreased by 19.0-25.5% 7

Clinical Decision Algorithm

Step 1: Assess Exacerbation History

• If the patient had ≥2 moderate exacerbations or ≥1 hospitalization for COPD in the past year → Triple therapy (Breztri) is strongly recommended 1

Step 2: Assess Symptom Burden

• If CAT score ≥10 or mMRC ≥2 despite Spiriva monotherapy → Escalation to triple therapy is appropriate 1

Step 3: Assess Lung Function

• If FEV1 <80% predicted with moderate-to-high symptoms → Triple therapy provides mortality benefit 1

Step 4: Consider Single-Inhaler Triple Therapy (SITT)

• Breztri as a single-inhaler triple therapy is preferred over multiple inhalers due to improved adherence and reduced risk of inhaler technique errors 1

Important Safety Considerations

Pneumonia Risk

• ICS-containing regimens (like Breztri) increase pneumonia risk, particularly in patients who smoke, are ≥55 years old, have BMI <25 kg/m², or have severe airflow limitation 9
• Monitor patients for signs and symptoms of pneumonia when using triple therapy 9

Other Common Adverse Effects

• Dysphonia (hoarseness) and oral candidiasis are more common with ICS-containing triple therapy compared to dual bronchodilators 6
• These effects can be minimized by rinsing the mouth after each use 6

Common Pitfalls to Avoid

Do Not Use Multiple LAMAs Together

• Never combine Spiriva (tiotropium) with Breztri (which contains glycopyrrolate), as this provides no additional benefit but increases anticholinergic side effects like dry mouth, urinary retention, and constipation 9
• The patient should stop Spiriva completely when starting Breztri 9

Do Not Delay Escalation in High-Risk Patients

• The mortality benefit of triple therapy is most pronounced in patients with high exacerbation risk and moderate-to-severe symptoms 1
• Real-world evidence supports earlier introduction of triple therapy in patients with persistent symptoms despite high-intensity therapy 7

Bottom Line for Clinical Practice

The pulmonologist's recommendation to switch from Spiriva to Breztri represents appropriate escalation of therapy based on current evidence showing that triple therapy reduces mortality, exacerbations, hospitalizations, and improves quality of life in patients with moderate-to-severe COPD who have high symptom burden or exacerbation risk. 1, 7 This is not simply replacing one medication with another that "works the same"—it is adding two additional medication classes (LABA and ICS) that work through complementary mechanisms to provide superior outcomes. 1, 5, 6